Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
BUSINESS
Takeda’s Dengue Vaccine Approved in Brazil
Takeda Pharmaceutical said on March 14 that it has received approval for its tetravalent dengue vaccine Qdenga in Brazil for the prevention of dengue caused by any of the four virus serotypes that can be found in individuals from four…
To read the full story
Related Article
- Takeda’s Dengue Vaccine Proves 4.5-Year Protection
June 10, 2022
- Takeda’s Dengue Vaccine Shows Long-Term Efficacy
May 25, 2021
- Takeda Files Dengue Vaccine Candidate in Europe
March 29, 2021
- Takeda’s Dengue Vaccine Candidate Showed Confirmed Protection Efficacy in PIII
November 8, 2019
BUSINESS
- Alloy Japan Looks to Turn iCAR-T into Shared Infrastructure, IND Filing Slated for 2026
August 20, 2025
- Marubeni Expands Pharma Sales Biz into Africa with Phillips Investment
August 20, 2025
- Daiichi Sankyo Snares First FDA Breakthrough Tag for ADC I-DXd
August 20, 2025
- Keytruda Retains Top Spot in Japan Drug Market in April-June: IQVIA
August 20, 2025
- Mounjaro Wins Double Crown in June GP Promotion: Intage
August 20, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…